Orris

Vitamin d deficiency affecting glycemic control articles

Reading File
Finding Sources
Searching PubMed

"vitamin D" AND "glycemic control" AND "type 2 diabetes"

Searching PubMed

"vitamin D deficiency" AND "insulin resistance" AND HbA1c

Reading Article

PMID: 39355942

Reading Article

PMID: 39290798

Reading Article

PMID: 40806075

Reading Article

PMID: 37901991

Finding Sources
Reading Article

PMID: 40616487

Reading Article

PMID: 36647067

Finding Sources
Finding Sources
Reading File
Reading File
I now have sufficient textbook content and PubMed meta-analysis data to deliver a thorough, evidence-based response. Here it is:

Vitamin D Deficiency and Glycemic Control: Evidence Summary

Mechanistic Background

Vitamin D influences glucose metabolism through several pathways:
1. Beta-cell function and insulin secretion Vitamin D receptors (VDRs) are expressed on pancreatic beta cells. Active vitamin D (calcitriol/1,25-dihydroxyvitamin D3) plays a positive role in regulating insulin secretion. As noted in Yamada's Textbook of Gastroenterology, "Calcitriol, the active form of vitamin D, also plays a positive role in the regulation of blood pressure, insulin secretion, immune response, and cell differentiation via its action through the vitamin D receptor." In the context of CKD, Brenner & Rector's The Kidney explicitly states that "both hyperparathyroidism and vitamin D deficiency may mediate insulin secretory abnormalities... pharmacologic doses of vitamin D3 have been reported to correct glucose tolerance."
2. Insulin resistance Brenner & Rector also notes that serum vitamin D concentrations are inversely correlated with "markers of insulin resistance and type 2 diabetes mellitus." Low vitamin D impairs VDR-mediated intracellular signaling in peripheral skeletal muscle, worsening the post-receptor defect underlying insulin resistance.
3. Nonskeletal roles (Harrison's 22nd ed., 2025) Harrison's states that "Vitamin D insufficiency may increase the risk of type 1 diabetes mellitus, cardiovascular disease (insulin resistance, hypertension, or low-grade inflammation)." However, Harrison's also adds a critical caveat: "Recent placebo-controlled studies did not show a therapeutic benefit of vitamin D for... risk of type 2 diabetes," noting that effects may differ based on baseline deficiency status.

Key Published Articles (Recent Meta-Analyses & Systematic Reviews)

1. Chen W et al. (2024) - Diabetes, Obesity & Metabolism [PMID: 39355942]

Updated systematic review and meta-analysis of 39 RCTs (n=2,982)
  • Vitamin D supplementation significantly reduced:
    • FBG: WMD -0.49 mmol/L (95% CI: -0.69 to -0.28)
    • HbA1c: WMD -0.30% (95% CI: -0.43 to -0.18)
    • HOMA-IR: WMD -0.39 (95% CI: -0.64 to -0.14)
    • Fasting insulin: WMD -1.31 μIU/mL
  • Effects were most prominent with short-term, high-dose supplementation in patients who were: vitamin D deficient at baseline, overweight, or had HbA1c ≥8%.
  • DOI: 10.1111/dom.15941

2. Afraie M et al. (2024) - Journal of Diabetes Research [PMID: 39290798]

Meta-analysis of trials from 1990 to January 2024
  • Vitamin D supplementation significantly decreased HbA1c (SMD: -0.15) and FBS (SMD: -0.28)
  • Also improved HDL and reduced LDL and SBP
  • 50,000 IU doses showed the most significant effect on diabetes control indicators
  • Weight, BMI, and disease duration could reduce the magnitude of benefit
  • PMC: PMC11407890

3. Probosari E et al. (2025) - Nutrients [PMID: 40806075]

Most recent meta-analysis (2025), 9 RCTs
  • At 12-week follow-up: significant reductions in insulin level (MD -3.59), HOMA-B (MD -50.35), hs-CRP, and HbA1c (MD -0.30%)
  • At 24-week follow-up: significant reduction in HOMA-IR (MD -0.38)
  • Notably also demonstrated an anti-inflammatory effect (hs-CRP reduction), linking vitamin D to the inflammation-glycemia axis
  • Concluded effects are "often modest and may diminish over time"
  • DOI: 10.3390/nu17152489

4. Farahmand MA et al. (2023) - BMC Endocrine Disorders [PMID: 36647067]

46 RCTs, 2,164 intervention subjects
  • Significant reductions in HbA1c (WMD -0.20%), FPG (WMD -5.02 mg/dL), and HOMA-IR (WMD -0.42)
  • Effect most prominent at higher doses and shorter intervention periods
  • Most efficacy in subjects with vitamin D deficiency at baseline
  • PMC: PMC9841647

5. Zhang XJ et al. (2025) - Biomedical and Environmental Sciences [PMID: 40616487]

Network meta-analysis of 40 RCTs comparing dosage strategies
  • Extremely high doses (≥4,000 IU/day) most effectively raised 25(OH)D levels
  • Extremely high doses reduced FBG vs. no treatment
  • Low doses (< 1,000 IU/day) significantly decreased HbA1c
  • Medium doses (1,000-2,000 IU/day) most effectively reduced fasting insulin
  • Key finding: dose-dependent increase in 25(OH)D but not necessarily a dose-dependent glycemic effect - lower doses may still benefit HbA1c
  • DOI: 10.3967/bes2025.066

6. Mi N et al. (2024) - Advances in Clinical and Experimental Medicine [PMID: 37901991]

Meta-analysis of 9 RCTs on vitamin D + 5 RCTs on smoking cessation
  • Vitamin D supplementation associated with improved insulin sensitivity: OR 0.52 (95% CI: 0.34-0.78, p=0.002)
  • Moderate BMI decline also observed
  • DOI: 10.17219/acem/171451

Summary Table

StudyYearn (RCTs)HbA1c EffectFBG EffectHOMA-IR Effect
Chen W et al.202439 RCTs-0.30%-0.49 mmol/L-0.39
Afraie M et al.2024MultipleSMD -0.15SMD -0.28-
Probosari E et al.20259 RCTs-0.30%Trend-0.38 (at 24 wk)
Farahmand MA et al.202346 RCTs-0.20%-5.02 mg/dL-0.42
Zhang XJ et al.202540 RCTsSig. (low dose)Sig. (EHDS)-

Key Clinical Takeaways

  1. Who benefits most: T2D patients with confirmed vitamin D deficiency (25(OH)D < 20 ng/mL), higher baseline HbA1c (≥8%), and overweight/obesity show the greatest glycemic improvement.
  2. Dosing: Both high-dose short-term and low-dose long-term regimens show benefit, but 50,000 IU supplementation has been highlighted as particularly effective. Dose-titration based on baseline 25(OH)D is recommended.
  3. Effect size: Modest but consistent - roughly 0.2-0.3% reduction in HbA1c and 0.4-0.5 mmol/L reduction in FBG across trials.
  4. Mechanism: Works via VDR-mediated insulin secretion enhancement, reduction of peripheral insulin resistance, and anti-inflammatory effects (hs-CRP reduction).
  5. Caveat: Harrison's 22nd edition (2025) notes that large placebo-controlled trials (e.g., VITAL) did not show benefit for T2D prevention in general populations - benefits appear most relevant in those who are actually deficient.
This is a shared conversation. Sign in to Orris to start your own chat.